| melanoma
Braftovi vs Imlygic
Side-by-side clinical, coverage, and cost comparison for melanoma.Deep comparison between: Braftovi vs Imlygic with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsImlygic has a higher rate of injection site reactions vs Braftovi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Imlygic but not Braftovi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Braftovi
Imlygic
At A Glance
Oral
Once daily
BRAF inhibitor
Intralesional injection
Every 2-3 weeks
Oncolytic viral therapy
Indications
- melanoma
- Colorectal Carcinoma
- Non-Small Cell Lung Carcinoma
- Melanoma
Dosing
melanoma, Non-Small Cell Lung Carcinoma 450 mg (six 75 mg capsules) orally once daily in combination with binimetinib until disease progression or unacceptable toxicity.
Colorectal Carcinoma 300 mg (four 75 mg capsules) orally once daily until disease progression or unacceptable toxicity, in combination with biweekly cetuximab and mFOLFOX6 or FOLFIRI, or weekly cetuximab.
Melanoma Initial dose up to 4 mL at 1 million PFU/mL intralesionally; second dose 3 weeks later up to 4 mL at 100 million PFU/mL; all subsequent doses every 2 weeks up to 4 mL at 100 million PFU/mL.
Contraindications
—
- Immunocompromised patients, including those with primary or acquired immunodeficiency, leukemia, lymphoma, AIDS or other clinical manifestations of HIV infection, or on immunosuppressive therapy
- Pregnant patients
Adverse Reactions
Most common (>=25%) Fatigue, nausea, vomiting, diarrhea, abdominal pain, arthralgia, peripheral neuropathy, decreased appetite, rash, constipation, musculoskeletal pain, hemorrhage, pyrexia.
Serious New primary malignancies, cardiomyopathy, hepatotoxicity, hemorrhage, uveitis, QT prolongation, embryo-fetal toxicity.
Most common (>=25%) Fatigue, chills, pyrexia, nausea, influenza-like illness, injection site pain
Serious Cellulitis (most common grade 3+ reaction), herpetic infection, injection site complications
Postmarketing Disseminated herpetic infections, including serious and fatal cases in immunocompromised patients
Pharmacology
Encorafenib is a kinase inhibitor that targets BRAF V600E as well as wild-type BRAF and CRAF, blocking constitutively activated BRAF kinase signaling driven by BRAF V600 mutations that stimulates tumor cell growth; in combination with binimetinib, it targets two kinases in the RAS/RAF/MEK/ERK pathway for greater anti-tumor activity.
Oncolytic viral therapy; genetically modified live attenuated HSV-1 that replicates within tumors causing lysis and release of tumor-derived antigens, and produces GM-CSF to promote an antitumor immune response; exact mechanism of action is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Braftovi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Imlygic
- Covered on 5 commercial plans
- PA (2/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Braftovi
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (0/8)
Imlygic
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Braftovi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Imlygic
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Braftovi Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAmgen Safety Net Foundation
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BraftoviView full Braftovi profile
ImlygicView full Imlygic profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.